QFT Plus Webinar Hub
QFT-Plus Webinar Hub

Expert tuberculosis webinars

TB screening with confidence

Welcome to the webinar hub for QuantiFERON-TB Gold Plus (QFT-Plus) and TB testing.

The WHO now recommends systematic testing and treatment of latent TB infection – and universally supports modern blood tests for patients at risk (1). It’s time to move on from the skin test and join the TB testing revolution with QFT-Plus.

To learn more about the benefits of QFT-Plus testing and hear about the latest testing guidelines from the CDC, IDSA, USCIS and more, watch our most recent webinars.

  • Is screening and treatment of latent TB the key to TB elimination?
    Tuberculosis continues to threaten the lives of people worldwide as each year 10 million people develop this disease. Join Dr. Jean-Pierre Zellweger as he discusses the 2019 WHO TB report, new preventive treatment regimens and the benefits of using QuantiFERON-TB Gold Plus as a primary screening method to help reach the End TB Strategy targets.
    Is screening and treatment of latent TB the key to TB elimination?
  • QuantiFERON -TB Gold Plus: Is your practice up to date?
    Recent publications show the potential of QFT-Plus technology for at-risk patient populations — including contact investigation, healthcare worker screening and immunocompromised patients. In this webinar, Dr. Masae Kawamura discusses the latest scientific advancements in TB testing, including a review of recent publications and a discussion of case scenarios applying the insights of QFT-Plus.
    QuantiFERON -TB Gold Plus: Is your practice up to date?
  • TST or IGRA in healthcare workers: The when and the why
    Healthcare providers (HCPs) are at increased risk of TB infection. In this webinar, Dr. Wendy Thanassi gives an overview of screening HCPs for TB infection. She discusses the risks of TB infection and latent TB reactivation in the occupational health setting and describes current testing guidelines. She also explains the operational and medical differences between the TST and modern TB blood tests (IGRAs).
    TST or IGRA in healthcare workers: The when and the why
  • Diagnosing tuberculosis infection in children: when, why and how?
    Children newly diagnosed with TB often indicate a recent community transmission event. They also carry increased risk of progressing to active TB disease. In this webinar, Dr. Lindsey Cameron investigates the value and efficacy of TB diagnostics in children. She explores the impact of COVID-19 on TB epidemiology, identifies TB risk factors, and compares the performance between the TST and IGRAs as diagnostic aids for these vulnerable patients.
    Latent tuberculosis infection in children
  • Insights on the development of a national health plan for TB
    Migrants are at increased risk for latent and active tuberculosis, and screening for latent TB infection is a critical component of a TB prevention and control strategy. Join Dr. Eskild Petersen as he discusses the the WHO goal of global elimination. Topics include migrant screening, the use of IGRA blood tests and the identification of at-risk populations.
    Insights on the development of a national health plan for TB
  • Protecting students from TB
    People living in dense housing arrangements – such as college dormitories – are at significantly increased risk of TB infection. Dr. Sonia Qasba describes recent TB exposures at US colleges, details testing recommendations from the ACHA and the CDC and describes how modern TB blood testing can improve the effectiveness and efficiency of college screening programs.
    Protecting students from TB
  • Management of TB infection in HIV co-infected patients
    People living with HIV are at increased risk for TB, and reliable surveillance is critical to protect their health. Join Dr. Delia Goletti to learn more about TB testing in patients living with HIV using QuantiFERON-TB Gold Plus. Topics include a review of published data and a discussion of the frontiers of TB diagnostic research.
    Management of TB infection in HIV co-infected patients
  • Occupational health screening for latent tuberculosis: an update
    The occupational health setting carries unique risks for TB infection and latent TB reactivation. Join Dr. Manish Pareek as he provides an overview of best practices for screening healthcare providers (HCPs) for TB infection, describes current global testing guidelines and provides a UK-specific perspective on TB screening in low-burden settings.
    Occupational health screening for latent tuberculosis: an update
  • Management of latent TB infection in patients requiring initiation of biologic therapy
    Join Dr. Vlad Nikolayevskyy as he provides an overview of the policies, practices and recent publications on screening patients requiring initiation of biologic therapy for TB infection. He also discusses new TB preventive treatment regimens and the use of IGRAs as a primary screening method.
    Manage latent TB infection prior to biologic therapy
  • Managing TB and HIV amidst the COVID-19 pandemic
    The COVID-19 pandemic has caused a global crisis with wide-reaching health and economic implications, including TB and HIV services. Join Dr. Sonia Qasba as she reviews screening for TB infection and prevention during these times, along with U.S. and global trends in COVID-19 epidemiology.
    Managing TB and HIV amidst the COVID-19 pandemic
  • The association between diabetes mellitus and latent TB infection
    Someone with untreated latent TB infection (LTBI) and diabetes is more likely to develop tuberculosis (TB) disease than someone without diabetes. In this webinar, Dr. Sonia Qasba journeys through the epidemiology, risk and treatment recommendations of diabetic patients with LTBI. She also discusses how diabetes potentiates TB and why TB predisposes one to hyperglycemia.
    The association between diabetes mellitus and latent TB infection
  • Latent TB infection testing, control and management in diabetes mellitus
    Type 2 diabetes is a risk factor for the development of active TB. In this webinar, Dr. Blanca I. Restrepo will describe the epidemiological landscape of TB and diabetes, with contrasting observations between adults and the elderly. Most notably, the elderly have a high prevalence of type 2 diabetes, yet this is not associated with higher odds of TB in this population. Finally, she will discuss the challenges for latent TB infection testing in the elderly.
    Risk-based TB screening: a primary care approach to TB elimination
  • Getting back to care – where will TB be after COVID-19?
    As the world urgently rebuilds disrupted core health services for TB, can we draw on the innovations that evolved during COVID-19 to eliminate TB? Join Dr. Wendy Thanassi as she discusses the impact of COVID-19 from a US and global perspective. She will also highlight the unexpected upside that all the world’s attention, money and innovations could bring to the global battle to End TB.
    Dr Wendy Thanassi  World TB Day 2022
  • The predictive value of IGRAs and the role of CD4+ and CD8+ T cells in the immune response to TB
    TB infection screening has dropped drastically due to COVID-19. Single visit tests, CD8 detection and automation – are we using all the tools we have to bridge the gap in TB care? In this webinar, Dr. Lei Gao (China) and Dr. Lucia Barcellini (Italy) will bring you perspectives on the future of TB diagnostics from both low- and high-burden TB settings.
    Dr Lei Gao World TB Day 2022
  • TB in children: Pediatric TB diagnosis and management
    Once infected with M. tuberculosis, children with vulnerable immune systems are the most at risk of progressing to active TB disease. How can we protect children from TB? Join Dr. Ann M Loeffler and Dr. Danilo Buonsenso, along with our moderator Dr. Riccardo Alagna, to understand how testing and treating pediatric TB infection can help prevent development of TB disease in children.
    World TB Day 2022
  • Immunosuppressive and biologic therapy: The utility of TB blood test (IGRAs
    Patients receiving immunosuppressive and biologic therapy are at increased risk for TB reactivation and disease progression. In this webinar, Dr. Shereen Mahmood explores the benefits interferon-gamma release assays and their application as a primary screening method to help protect patients at risk. She provides a low-TB-burden, US perspective, describing best practices and TB screening algorithms that are endorsed by the American College of Rheumatology.
    Best practices in tuberculosis screening and prevention in long-term care facilities
  • TB in long-term care: Testing strategies that deliver speed and accuracy
    TB remains a real danger to nursing home residents and staff, but many LTC providers are still under-testing, using hundred-year-old testing tools and bogging down staff onboarding with an outdated approach. During this webinar, Dr. Burdsall provides low-burden US perspective on TB prevention in long-term care, highlighting US CDC guidelines and describing how new strategies can save providers time and — potentially — money.
    Finding TB in the crowd: testing strategies for today’s skilled nursing facilities
  • Renal disease and TB – understanding risk and improving management
    Patients experiencing renal disease (CKD), hemodialysis and kidney transplantation all face an increased risk of progression from TB infection to TB disease. In this webinar, Dr. Onn Min Kon, lead of TB Service at the Imperial College Healthcare NHS Trust, explores the interaction between kidney disease and TB. He highlights current US and European guidelines for TB screening as well as the presentations and treatment of active TB.
    TB or not TB: Testing strategies that deliver speed and accuracy
  • 2022 EULAR guidelines for TB screening in adults with rheumatic diseases
    Pharmaceutical labeling reinforces that TB testing is critical when evaluating treatment options for rheumatic disorders. In 2022, the European Alliance of Associations for Rheumatology (EULAR) published new recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Join Dr. James Galloway, co-author of the guidelines, as he provides an overview of the best practices in TB testing.
    Hepatitis testing saves lives
  • Is screening and treatment of latent TB the key to TB elimination?
    Is screening and treatment of latent TB the key to TB elimination?
  • QuantiFERON -TB Gold Plus: Is your practice up to date?
    QuantiFERON -TB Gold Plus: Is your practice up to date?
  • TST or IGRA in healthcare workers: The when and the why
    TST or IGRA in healthcare workers: The when and the why
  • Latent tuberculosis infection in children
    Diagnosing tuberculosis infection in children: when, why and how?
  • Insights on the development of a national health plan for TB
    Insights on the development of a national health plan for TB
  • Protecting students from TB
    Protecting students from TB
  • Management of TB infection in HIV co-infected patients
    Management of TB infection in HIV co-infected patients
  • Occupational health screening for latent tuberculosis: an update
    Occupational health screening for latent tuberculosis: an update
  • Manage latent TB infection prior to biologic therapy
    Management of latent TB infection in patients requiring initiation of biologic therapy
  • Managing TB and HIV amidst the COVID-19 pandemic
    Managing TB and HIV amidst the COVID-19 pandemic
  • The association between diabetes mellitus and latent TB infection
    The association between diabetes mellitus and latent TB infection
  • Risk-based TB screening: a primary care approach to TB elimination
    Latent TB infection testing, control and management in diabetes mellitus
  • Dr Wendy Thanassi  World TB Day 2022
    Getting back to care – where will TB be after COVID-19?
  • Dr Lei Gao World TB Day 2022
    The predictive value of IGRAs and the role of CD4+ and CD8+ T cells in the immune response to TB
  • World TB Day 2022
    TB in children: Pediatric TB diagnosis and management
  • Best practices in tuberculosis screening and prevention in long-term care facilities
    Immunosuppressive and biologic therapy: The utility of TB blood test (IGRAs
  • Finding TB in the crowd: testing strategies for today’s skilled nursing facilities
    TB in long-term care: Testing strategies that deliver speed and accuracy
  • TB or not TB: Testing strategies that deliver speed and accuracy
    Renal disease and TB – understanding risk and improving management
  • Hepatitis testing saves lives
    2022 EULAR guidelines for TB screening in adults with rheumatic diseases

References:

1. WHO. (2018) Latent tuberculosis infection: Updated and consolidated guidelines for programmatic management. WHO/CDS/TB/2018.4.

QFT-Plus is an in vitro diagnostic aid for detection of Mycobacterium tuberculosis infection. QFT-Plus is an indirect test for M. tuberculosis infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations.

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit instructions for use or user operator manual. QIAGEN instructions for use and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services (or your local distributor).